Brief: Kaken Pharmaceutical signs agreement with Dong-A ST for Clenafin/Jublia in Korea

Dong-A ST

31/05/2016 04:03

May 31 (Reuters) - Kaken Pharmaceutical Co Ltd  4521.T  : 
     
    * Says Kaken Pharmaceutical  4521.T   and A Korea-based firm 
Dong-A ST Co Ltd  170900.KS  concluded an exclusive distribution 
agreement for the topical formulation for Onychomycosis 
"Clenafin / Jublia" in Korea 
    * Says according to the agreement, Kaken hereby grant to 
Dong-A the exclusive right for development and sales of the 
Product in Korea 
         
    Source text in Japanese: https://goo.gl/TTVUJU 
    Further company coverage:[4521.T ] 170900.KS  
 
 (Beijing Headline News) 
 ((Beijing.HeadlineNews@thomsonreuters.com; +86 62674724; 
Reuters Messaging: Cheng.Li@thomsonreuters.com@reuters.net))